On Monday, May 18, the next meeting of the Transparency Council.
What will the AOTMiT Transparency Council address at its upcoming meeting?
Published May 14, 2026 21:12
Źródło: AOTMiT
The agenda includes:
1 Prepare a position on the qualification of the Mental Health Center's health care benefit.
2 Prepare a position paper on the evaluation of the drug Sialanar (glycopyrronii bromidum) for the indication: symptomatic treatment of severe sialorrhea (chronic pathological salivation) in children and adolescents aged 3 years and older with cerebral palsy.
3 Prepare a position paper on the evaluation of the drug Ozempic (semaglutidum) for the indication: type 2 diabetes mellitus in patients treated with at least one hypoglycemic drug, with HbA1c ≥ 7.0%, with BMI ≥27 kg/m2, and very high cardiovascular risk understood as: confirmed cardiovascular disease, or damage to other organs manifested by: proteinuria or left ventricular hypertrophy or retinopathy, or the presence of 2 or more major risk factors among the following: age ≥ 55 years for men, ≥60 years for women, dyslipidemia, hypertension, smoking.
4 Prepare a position paper on the evaluation of the drug Omvoh (mirikizumabum) under the drug program B.32. "Treatment of patients with Crohn's disease (ICD-10: K50)".
Source: AOTMiT
